← back to search

Carlos Cordon‐Cardo

Mount Sinai Health System · US
Area of research
Surgery · Oncology
Research interest
Research interests include Bladder and Urothelial Cancer Treatments, Cancer-related Molecular Pathways, Prostate Cancer Treatment and Research, and Epigenetics and DNA Methylation.
h-index
155
citations
97,715
works
935
NIH funding
primary concept
Medicine
email

Recent publications

A tumor-promoting inflammatory SPP1+ macrophage-IL-6-CRP axis drives immune dysfunction in bladder cancer.
2026cited by 0position: contributordoi
Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin-driven Tumor Progression and Immune Escape in Prostate Cancer.
2025cited by 0position: contributordoi
Figure S1 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
2025cited by 0position: contributordoi
Supplementary Table S1 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
2025cited by 0position: contributordoi
Figure S3 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
2025cited by 0position: contributordoi
Figure S6 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
2025cited by 0position: contributordoi
Supplementary Table S2 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
2025cited by 0position: contributordoi
Data from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
2025cited by 0position: contributordoi
Figure S7 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
2025cited by 0position: contributordoi
Figure S5 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
2025cited by 0position: contributordoi
Figure S4 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
2025cited by 0position: contributordoi
Figure S2 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
2025cited by 0position: contributordoi
Supplementary Table S3 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
2025cited by 0position: contributordoi
Extracellular vesicles, RNA sequencing, and bioinformatic analyses: Challenges, solutions, and recommendations
Journal of Extracellular Vesicles 2024cited by 88position: middledoi
Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer.
2023cited by 14position: contributordoi
The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, decreases DNA damage repair, and predicts therapy responses.
2023cited by 5position: contributordoi
The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, decreases DNA damage repair, and predicts therapy responses.
2023cited by 1position: contributordoi
Evaluation and validation of an RT‐PCR assay for specific detection of monkeypox virus (MPXV)
Journal of Medical Virology 2022cited by 74position: middledoi
Artificial intelligence-derived neurofibrillary tangle burden is associated with antemortem cognitive impairment
Acta Neuropathologica Communications 2022cited by 46position: middledoi
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization
mSphere 2022cited by 30position: middledoi
Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years
Breast Cancer Research 2022cited by 24position: middledoi
circCsnk1g3- and circAnkib1-regulated interferon responses in sarcoma promote tumorigenesis by shaping the immune microenvironment.
2022cited by 18position: contributordoi
Antemortem detection of Parkinson’s disease pathology in peripheral biopsies using artificial intelligence
Acta Neuropathologica Communications 2022cited by 16position: middledoi
Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience.
2021cited by 187position: contributordoi
Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms
Gastroenterology 2021cited by 160position: middledoi
Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave.
2021cited by 20position: contributordoi
An inflammatory cytokine signature predicts COVID-19 severity and survival.
2020cited by 2,062position: contributordoi
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Science 2020cited by 1,261position: lastdoi
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
2020cited by 969position: contributordoi
SARS-CoV-2 viral load predicts COVID-19 mortality
The Lancet Respiratory Medicine 2020cited by 564position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

· 19 papers (2020–2025) · 12 papers (2025–2025)Adam Ertel · Cancer Clinic12 papers (2025–2025)Vijayakumar Jawalagatti · WinnMed12 papers (2025–2025)Peiyao Li · First Affiliated Hospital of Kunming Medical University12 papers (2025–2025)Jacob J Orme · The University of Texas at Austin12 papers (2025–2025)Michael Xu · China Medical University12 papers (2025–2025) · 12 papers (2025–2025)Shijia Zhu · Chuzhou University12 papers (2025–2025)Haidong Dong · Sylvester Comprehensive Cancer Center12 papers (2025–2025)S. Aidan Quinn · Cancer Genetics (United States)12 papers (2025–2025)Veronica Rodriguez-Bravo · WinnMed12 papers (2025–2025) · 12 papers (2025–2025)Josep Domingo-Domenech · WinnMed12 papers (2025–2025)Perumalraja Kirthika · Jeonbuk National University12 papers (2025–2025)Emmanuel S. Antonarakis · University of Minnesota12 papers (2025–2025)Elisabeth I. Heath · University Hospitals Seidman Cancer Center12 papers (2025–2025)Haojie Huang · First Affiliated Hospital of Xi'an Jiaotong University12 papers (2025–2025)Marc Carceles-Cordon · Sidney Kimmel Cancer Center12 papers (2025–2025)Daniel P. Petrylak · Yale Cancer Center12 papers (2025–2025)